Wednesday, 4 November 2026
M
Meridian Globe
Live briefing
Democrats retake control of the US Congress in a heavy blow to Trump— MercoPress 南锥体通讯Nidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei AsiaUS tech giants' hidden AI debt swells 90% to $3.2tn in 6 months— 日经 Nikkei AsiaFukushima tries to reinvent itself as hub for drones, robots and rockets— 日经 Nikkei AsiaJapan's Yamato targets 'leaner' delivery service in push for profit: president— 日经 Nikkei AsiaDemocrats retake control of the US Congress in a heavy blow to Trump— MercoPress 南锥体通讯Nidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei AsiaUS tech giants' hidden AI debt swells 90% to $3.2tn in 6 months— 日经 Nikkei AsiaFukushima tries to reinvent itself as hub for drones, robots and rockets— 日经 Nikkei AsiaJapan's Yamato targets 'leaner' delivery service in push for profit: president— 日经 Nikkei Asia

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

Source Nature 医学研究2d ago
Summary

We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.

Open original
Desk
Health
Region
Global
Language
English
Item ID
health-00a74bed

Comments 0 comments

No comments yet. Be the first.

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials · Meridian Globe